The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

van Zonneveld, M; Flink, HJ; Verhey, E; Senturk, H; Zeuzem, S; Akarca, US; Cakaloglu, Y; Simon, C; So, TMK; Gerken, G; de Man, RA; Hansen, BE; Schalm, SW; Janssen, HLA

doi:10.1111/j.1365-2036.2005.02453.x

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

van Zonneveld M., Flink H., Verhey E., Senturk H., Zeuzem S., Akarca U., ...More

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.21, no.9, pp.1163-1171, 2005 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 21 Issue: 9
Publication Date: 2005
Doi Number: 10.1111/j.1365-2036.2005.02453.x
Title of Journal : ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Page Numbers: pp.1163-1171

Abstract

Background: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events.